Top Markets
#1 Helium Helium +109.41%
#2 MowCat MowCat +103.90%
#3 Seeker Seeker +74.55%
#4 Pons Pons +47.43%
#5 AI XOVIA AI XOVIA +39.39%
#6 UnifAI Network UnifAI Network +33.34%
#7 Bounce Bounce +30.38%
#8 Tensor Tensor +22.88%
#9 Zylo Ecosystem Zylo Ecosystem +21.26%
#10 pipedog pipedog +20.42%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
BridgeBio Oncology Therapeutics Inc. BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc.

BBOT
Rank in Stocks #11443
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical... BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Share Price
$8.74
Last synced: 2026-08-28
Market Cap
$699.74M
Change (1 day)
-4.85%
Change (1 year)
-2.29%
Country
US
Trade BridgeBio Oncology Therapeutics Inc. (BBOT)

Category

Healthcare
Revenue for BridgeBio Oncology Therapeutics Inc. (BBOT)
Revenue in Aug 2026 TTM: 0
According to BridgeBio Oncology Therapeutics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BridgeBio Oncology Therapeutics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH